CFHR3-CFHR1 Deletion Does NOT Require Combined Liver-Kidney Transplant
Patients with atypical hemolytic uremic syndrome (aHUS) due to CFHR3-CFHR1 deletion do not require combined liver-kidney transplantation and can be successfully managed with isolated kidney transplantation, particularly with complement inhibitor therapy. This is fundamentally different from complement factor H (CFH) mutations, where the liver produces the defective protein.
Key Distinction: CFHR3-CFHR1 Deletion vs CFH Mutations
Why Combined Transplant is NOT Needed for CFHR3-CFHR1 Deletion
- CFHR3-CFHR1 deletion represents a loss of regulatory proteins (FHR1 and FHR3), not a production of defective complement factor H 1
- The liver is not producing a pathogenic protein that needs to be replaced, unlike CFH mutations where the liver synthesizes defective Factor H 2
- Successful isolated kidney transplantation without prophylactic eculizumab has been documented in CFHR3-CFHR1 deletion patients 3
When Combined Liver-Kidney Transplant IS Indicated
Combined liver-kidney transplantation is specifically reserved for patients with CFH mutations (not CFHR deletions):
- CFH is predominantly synthesized in the liver, making liver transplantation necessary to provide a source of normal Factor H 2
- Isolated kidney transplantation in CFH mutation patients results in high recurrence rates and allograft failure 2
- Combined LT-KT in CFH mutation patients prevents aHUS recurrence and eliminates the need for ongoing plasma therapy 2
Clinical Evidence for CFHR3-CFHR1 Deletion Management
Transplant Outcomes
- CFHR3-CFHR1 deletion is found in approximately 30% of the general population and is not classically linked to aHUS as a sole causative factor 4
- It acts as a susceptibility factor (a "first hit") that requires additional triggers to manifest disease 4
- Post-transplant patients with CFHR3-CFHR1 deletion who developed aHUS responded well to eculizumab therapy 4
Treatment Approach
The primary management strategy for CFHR3-CFHR1 deletion-associated aHUS is complement inhibition with eculizumab or ravulizumab 5:
- Genetic testing should identify CFHR1-5, CFH, C3, CD46, CFI, THBD, DGKE, and CFB variants 5
- Treatment decisions should be made at rare disease reference centers with multidisciplinary teams 5
- Close monitoring is essential, as CFHR3-CFHR1 deletion patients may initially show resistance to standard eculizumab dosing but respond to dose intensification 3
Important Clinical Caveats
Risk Stratification
- CFHR3-CFHR1 deletion alone is insufficient to cause aHUS; additional triggers (calcineurin inhibitors, rejection, infections, ischemia-reperfusion injury) are typically required 4
- Heterozygous deletion occurs commonly in the population without disease manifestation 6
- The deletion results from nonallelic homologous recombination between long interspersed nuclear elements flanking these genes 6
Transplant Considerations
- Kidney transplantation can trigger aHUS recurrence in susceptible individuals, whether as recurrent disease or de novo in the graft 5
- Absence of marked thrombocytopenia or anemia post-transplant should not exclude TMA diagnosis 5
- Patients on kidney transplant waiting lists without precise genetic diagnosis should be re-evaluated 5
Monitoring After Treatment Discontinuation
- Discontinuing eculizumab/ravulizumab carries a 10-20% risk of relapse 5
- Patients should be thoroughly assessed for risk factors before discontinuation 5
- Close monitoring parameters include C3, C4, CH50, and AP50 levels 5
Practical Algorithm
For CFHR3-CFHR1 deletion-associated aHUS:
- Confirm genetic diagnosis with next-generation sequencing and multiplex ligation-dependent probe amplification 5
- Initiate complement inhibitor therapy (eculizumab/ravulizumab) for acute disease 5
- Consider dose intensification if initial response is inadequate 3
- Proceed with isolated kidney transplantation when indicated (combined liver-kidney transplant is NOT required) 3
- Maintain close surveillance for triggers and recurrence 4
For CFH mutations (different scenario):